Last reviewed · How we verify
MAGNE-B6 Oral Solution — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
MAGNE-B6 Oral Solution (MAGNE-B6 Oral Solution) — Opella Healthcare Group SAS, a Sanofi Company.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| MAGNE-B6 Oral Solution TARGET | MAGNE-B6 Oral Solution | Opella Healthcare Group SAS, a Sanofi Company | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- MAGNE-B6 Oral Solution CI watch — RSS
- MAGNE-B6 Oral Solution CI watch — Atom
- MAGNE-B6 Oral Solution CI watch — JSON
- MAGNE-B6 Oral Solution alone — RSS
Cite this brief
Drug Landscape (2026). MAGNE-B6 Oral Solution — Competitive Intelligence Brief. https://druglandscape.com/ci/magne-b6-oral-solution. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab